Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06351345 · ClinicalTrials.gov registry record · Phase 2

129 Xenon Imaging in Patients Treated With Sotatercept

A Phase 2 study of Pulmonary Hypertension and Pulmonary Arterial Hypertension, sponsored by Bastiaan Driehuys.

Recruiting
Registry status
Phase 2
Development phase
14
Enrollment target
1
Study location

NCT06351345 is a Phase 2 study of Pulmonary Hypertension and Pulmonary Arterial Hypertension that is actively recruiting participants, run by Bastiaan Driehuys. The registered enrollment target is 14 participants, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06351345, a Phase 2 study of Pulmonary Hypertension and Pulmonary Arterial Hypertension, is actively recruiting participants, sponsored by Bastiaan Driehuys.

RECRUITING
Registry status
Phase 2
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

Determine the ability of 129Xe MRI/MRS biomarker signatures to non-invasively monitor pulmonary vascular reverse remodeling induced by sotatercept in pulmonary arterial hypertension (PAH).

Interventions

  • DRUG 129Xe Hyperpolarized

Study Locations (1)

North Carolina

  • Duke University Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2025-10-27
Est. Completion 2030-02-04
Phase Phase 2

Sponsor

Bastiaan Driehuys

16 total trials

What the Registry Record Tells You About NCT06351345

The ClinicalTrials.gov registry entry for NCT06351345 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (98% lower). The listed sponsor is Bastiaan Driehuys, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 1 intervention - of which 129Xe Hyperpolarized is the first listed.

NCT06351345 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT06351345 about?

NCT06351345 is a clinical study titled "129 Xenon Imaging in Patients Treated With Sotatercept". Determine the ability of 129Xe MRI/MRS biomarker signatures to non-invasively monitor pulmonary vascular reverse remodeling induced by sotatercept in pulmonary arterial hypertension (PAH).

What is the current status of trial NCT06351345?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2025-10-27. Estimated completion is 2030-02-04.

What conditions does trial NCT06351345 study?

This clinical trial studies the following conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension.

What interventions are being tested in trial NCT06351345?

The interventions under investigation include: 129Xe Hyperpolarized (DRUG).

Who is sponsoring clinical trial NCT06351345?

This trial is sponsored by Bastiaan Driehuys, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06351345 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pulmonary Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.